Innovative pharma investment in Canada has been underreported by 20% in the past, new study shows

21 June 2011

According to a new study by analysts at KPMG in conjunction with Canada’s pharmaceutical trade group Rx&D, there was 20% under-reporting of investment. Rx&D’s president, Russell Williams, says: “The report is clear and offers a more accurate picture of the contributions made by Rx&D members in Canada. With close to C$1.5 billion ($1.53 billion) investment in 2010, the report proves that Rx&D members are amongst the largest private sector investors in Health Research in this country and make a very important contribution to communities.”

He noted that the report demonstrates that the measurements used in the past did not capture the full extent and breadth of industry contributions to Canada and Canadians and, over the past few years, “the nature of pharmaceutical research and development activity has undergone significant change as research and business models have evolved, becoming more collaborative and global.”

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK









Company Spotlight



More Features in Pharmaceutical